X4 Pharmaceuticals, Inc. Made Headway

X4 Pharmaceuticals, Inc. (XFOR:NASDAQ) shot up at $0.41, a gain of 47.9%. The stock got featured on our News Catalysts scanner on Thu, Nov 14, 2024 at 01:54 PM in the 'BIOTECH' category. From Thu, Oct 31, 2024, the stock recorded 70.00% Up Days and 54.55% Green Days

The stock spiked on Tue, Nov 12, 2024 at $0.68 with a volume of 2M+.

About X4 Pharmaceuticals, Inc. (XFOR:NASDAQ)

Arsanis Inc discovers and develops monoclonal antibodies for the targeted immunotherapy of serious infections. The company's monoclonal antibodies selectively focus on specific pathogens and pathogenic processes which address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. Few of its products candidates are ASN100, for prevention of pneumonia in high risk, mechanically ventilated patients; ASN500, for prevention of respiratory Syncytial virus; ASN300 and ASN200, for prevention and treatment of bacterial infections.